{"disease":{"id":"advanced-pancreatic-cancer","name":"advanced pancreatic cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06073431","title":"LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT04789980","title":"Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY","phase":"","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06028724","title":"A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","phase":"","overall_status":"RECRUITING","enrollment_count":782,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT05751850","title":"HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":778,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05380414","title":"Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05653453","title":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":512,"lead_sponsor_name":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT06714604","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT06944587","title":"A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06958328","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":356,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06799637","title":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT06360354","title":"A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02526017","title":"Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":true},{"nct_id":"NCT02184663","title":"Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":313,"lead_sponsor_name":"GERCOR - Multidisciplinary Oncology Cooperative Group","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05074589","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03126435","title":"EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"SynCore Biotechnology Co., Ltd.","has_results":true},{"nct_id":"NCT04332653","title":"NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"NeoImmuneTech","has_results":true},{"nct_id":"NCT03336216","title":"A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04805307","title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT07021066","title":"Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT03468335","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT04396821","title":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Suzhou Transcenta Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT04469556","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06492941","title":"A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":142,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04678648","title":"A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"RasCal Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03443492","title":"SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT04682431","title":"A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04821284","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Flemming Forsberg","has_results":false},{"nct_id":"NCT06669078","title":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT04222413","title":"Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05580445","title":"Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":114,"lead_sponsor_name":"Shouyao Holdings (Beijing) Co. LTD","has_results":false},{"nct_id":"NCT04707118","title":"Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":106,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04247126","title":"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Syros Pharmaceuticals","has_results":false},{"nct_id":"NCT07326137","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","phase":"","overall_status":"RECRUITING","enrollment_count":103,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04789486","title":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04801095","title":"A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Wellmarker Bio","has_results":false},{"nct_id":"NCT04931381","title":"Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT05733000","title":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT04172532","title":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04005690","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT07446270","title":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03682289","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT00819169","title":"QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":89,"lead_sponsor_name":"NantCell, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}